Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
1.700
-0.060 (-3.41%)
At close: Apr 28, 2026, 4:00 PM EDT
1.730
+0.030 (1.76%)
After-hours: Apr 28, 2026, 6:16 PM EDT
Pyxis Oncology Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Pyxis Oncology stock have an average target of 7.00, with a low estimate of 5.00 and a high estimate of 8.00. The average target predicts an increase of 311.76% from the current stock price of 1.70.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 24, 2026.
Analyst Ratings
The average analyst rating for Pyxis Oncology stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +370.59% | Mar 24, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +311.76% | Mar 24, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $8 → $5 | Buy | Maintains | $8 → $5 | +194.12% | Dec 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $7 | Strong Buy | Maintains | $5 → $7 | +311.76% | Dec 19, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Maintains $5 → $8 | Buy | Maintains | $5 → $8 | +370.59% | Nov 24, 2025 |
Financial Forecast
Revenue This Year
44.63K
from 13.86M
Decreased by -99.68%
Revenue Next Year
3.19M
from 44.63K
Increased by 7,043.98%
EPS This Year
-1.36
from -1.28
EPS Next Year
-1.40
from -1.36
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 367,500 | 26.3M | ||||||
| Avg | 44,625 | 3.2M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -97.3% | 58,723.5% | ||||||
| Avg | -99.7% | 7,044.0% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.18 | -1.07 | ||||||
| Avg | -1.36 | -1.40 | ||||||
| Low | -1.53 | -1.77 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.